4//SEC Filing
BAILEY MICHAEL P 4
Accession 0000899243-23-002183
CIK 0001325879other
Filed
Jan 18, 7:00 PM ET
Accepted
Jan 19, 5:11 PM ET
Size
32.4 KB
Accession
0000899243-23-002183
Insider Transaction Report
Form 4
BAILEY MICHAEL P
Chief Commercial Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−3,249→ 0 totalExercise: $77.20Exp: 2023-01-24→ Common Stock (3,249 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−16,750→ 0 totalExercise: $15.70Exp: 2024-06-19→ Common Stock (16,750 underlying) - Disposition to Issuer
Common Stock
2023-01-19$15.00/sh−333,167$4,997,505→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−35,302→ 0 totalExercise: $5.60Exp: 2030-02-05→ Common Stock (35,302 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−11,999→ 0 totalExercise: $25.10Exp: 2023-06-26→ Common Stock (11,999 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−90,000→ 0 totalExercise: $8.40Exp: 2025-01-06→ Common Stock (90,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−75,366→ 0 totalExercise: $6.00Exp: 2027-02-07→ Common Stock (75,366 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−7,499→ 0 totalExercise: $17.70Exp: 2024-01-29→ Common Stock (7,499 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−46,000→ 0 totalExercise: $10.80Exp: 2026-01-07→ Common Stock (46,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−99,999→ 0 totalExercise: $30.80Exp: 2028-02-01→ Common Stock (99,999 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−93,500→ 0 totalExercise: $6.20Exp: 2029-02-06→ Common Stock (93,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−275,100→ 0 totalExercise: $9.12Exp: 2031-02-05→ Common Stock (275,100 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−625,192→ 0 totalExercise: $3.67Exp: 2032-02-15→ Common Stock (625,192 underlying)
Footnotes (2)
- [F1]Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration.
- [F2]This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Documents
Issuer
AVEO PHARMACEUTICALS, INC.
CIK 0001325879
Entity typeother
Related Parties
1- filerCIK 0001255856
Filing Metadata
- Form type
- 4
- Filed
- Jan 18, 7:00 PM ET
- Accepted
- Jan 19, 5:11 PM ET
- Size
- 32.4 KB